News
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.
U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of ...
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections.
A promising path to fighting COVID and other coronaviruses may have been based on a serious mistake. Scientists had zeroed in ...
Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback